Factor V Leiden Mutation PCR Test at Chughtai Lab Lahore

Factor V Leiden (FVL) Mutation Detection by PCR at Chughtai Lab

Factor V Leiden (FVL) is a genetic mutation that significantly increases the risk of developing abnormal blood clots, a condition known as thrombophilia. This mutation occurs in the F5 gene, which provides instructions for making the factor V protein. Factor V plays a critical role in the coagulation cascade, the series of chemical reactions that lead to the formation of blood clots in response to injury. Under normal physiological conditions, an enzyme called activated protein C (APC) inactivates factor V to prevent clots from growing too large. However, the Factor V Leiden mutation alters the structure of the factor V protein, making it resistant to inactivation by APC. This resistance leads to a prolonged active state of factor V, promoting excess thrombin generation and a hypercoagulable state. At Chughtai Lab, Pakistan’s leading diagnostic network, we offer advanced molecular detection of the Factor V Leiden mutation using Polymerase Chain Reaction (PCR) technology. This highly sensitive and specific genetic test is crucial for identifying individuals at risk for venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE), as well as managing recurrent pregnancy complications.

The molecular detection of the Factor V Leiden mutation by PCR at Chughtai Lab is performed by analyzing DNA extracted from a patient’s blood sample. PCR technology allows for the amplification of the specific region of the F5 gene containing the mutation (specifically the G1691A single nucleotide polymorphism, where guanine is replaced by adenine at position 1691). This mutation results in the substitution of the amino acid glutamine for arginine at position 506 (Arg506Gln) in the factor V protein, which is the primary cleavage site for activated protein C. By utilizing real-time PCR or restriction fragment length polymorphism (RFLP) analysis, our specialized molecular biology department can precisely determine whether a patient is homozygous (carrying two copies of the mutated gene), heterozygous (carrying one mutated copy and one normal copy), or wild-type (carrying two normal copies). This genetic distinction is of paramount clinical importance, as the risk of thrombosis varies dramatically between heterozygous and homozygous individuals. Identifying this mutation early allows clinicians to implement targeted prophylactic strategies, make informed decisions regarding anticoagulation therapy, and provide personalized counseling regarding lifestyle and medical risks.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the Factor V Leiden Mutation Detection by PCR at Chughtai Lab is straightforward, as genetic testing does not require extensive physical preparation. Patients should observe the following guidelines to ensure a smooth testing process:

• No Fasting Required: You do not need to fast before this test. You may eat and drink normally prior to your appointment.
• Medication Disclosure: Inform your healthcare provider and the laboratory staff about all medications you are currently taking, especially anticoagulants (such as warfarin, heparin, or direct oral anticoagulants like rivaroxaban and apixaban). While these medications do not interfere with the PCR genetic analysis, they are critical for your overall clinical assessment.
• Hydration: Staying well-hydrated is recommended, as it makes the venipuncture process easier by ensuring your veins are full and accessible.
• No Special Timing: The blood sample can be collected at any time of the day, regardless of your hormonal cycle or medication schedule.
• Prior Testing History: If you have had previous blood transfusions or a bone marrow transplant, inform the laboratory, as these procedures can introduce donor DNA and potentially affect the accuracy of genetic testing.

During the Procedure

The collection of the sample for the Factor V Leiden PCR test at Chughtai Lab follows standard clinical protocols designed for patient safety and comfort:

• Patient Positioning: You will be asked to sit comfortably in a phlebotomy chair. The phlebotomist will ask you to extend your arm and rest it on a supportive surface.
• Site Selection and Sanitization: The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the crook of the elbow). The skin over the selected vein will be thoroughly sanitized using an antiseptic swab to prevent contamination.
• Tourniquet Application: A tight elastic band (tourniquet) will be applied around your upper arm to increase pressure in the veins, making them more visible and easier to access.
• Sample Collection: A sterile, single-use needle will be gently inserted into the vein. A specific volume of blood will be drawn into an EDTA tube (usually a purple-top tube), which contains an anticoagulant that preserves the cellular components and DNA in the blood.
• Needle Removal and Pressure: Once the sample is collected, the tourniquet will be released, and the needle will be carefully withdrawn. A sterile cotton ball or gauze pad will be pressed onto the puncture site to stop any bleeding.
• Bandaging: A small adhesive bandage will be applied over the site. You will be advised to keep pressure on the area for a few minutes to prevent bruising.
• Duration and Experience: The entire venipuncture procedure takes less than five minutes. You may feel a brief, mild pinch when the needle enters the skin, but the process is generally painless.
• Safety and Processing: All samples are labeled with unique bar codes at the point of collection to ensure absolute traceability. The sample is then transported under controlled temperature conditions to our centralized molecular biology laboratory for DNA extraction and PCR analysis.

When is a Factor V Leiden (FVL) Mutation Detection by PCR Performed?

Unexplained Venous Thromboembolism (VTE)

Physicians frequently request the Factor V Leiden PCR test when a patient experiences an unprovoked venous thromboembolism, such as deep vein thrombosis (DVT) in the leg or a pulmonary embolism (PE) in the lungs. An unprovoked clot is one that occurs without any obvious external triggers, such as major orthopedic surgery, prolonged immobilization during travel, or active malignancy. Identifying the underlying genetic cause helps clinicians determine the appropriate duration of anticoagulant therapy, as patients with hereditary thrombophilia have a significantly higher risk of recurrent clotting events once treatment is discontinued.

Thrombosis at a Young Age

Developing a blood clot before the age of 50 is clinically atypical and strongly suggests an underlying hereditary predisposition. When a young patient presents with a DVT or PE, the clinical team will initiate a thrombophilia workup, with the Factor V Leiden mutation test being the primary investigation. Detecting the mutation in young patients is vital for long-term health planning, as it guides decisions regarding future high-risk scenarios, such as surgeries, long-haul flights, or prolonged bed rest, where temporary prophylactic anticoagulation may be required to prevent life-threatening clots.

Recurrent Pregnancy Loss and Obstetric Complications

The Factor V Leiden mutation is associated with an increased risk of obstetric complications, including recurrent pregnancy loss (typically defined as two or more unexplained miscarriages), severe preeclampsia, intrauterine growth restriction (IUGR), and placental abruption. During pregnancy, the body naturally enters a hypercoagulable state to prevent excessive bleeding during delivery. In women with the FVL mutation, this hypercoagulability is compounded, potentially leading to microthrombi (tiny blood clots) in the placental vasculature, which can compromise fetal blood supply. Identifying the mutation allows obstetricians to prescribe low-molecular-weight heparin (LMWH) and low-dose aspirin to improve pregnancy outcomes.

Thrombosis in Atypical Anatomical Sites

While most blood clots occur in the deep veins of the lower extremities, some individuals develop clots in unusual locations. These include the cerebral venous sinuses (leading to stroke-like symptoms), portal vein, hepatic vein (Budd-Chiari syndrome), mesenteric veins (causing bowel ischemia), or renal veins. Thrombosis in these atypical vascular beds is a strong clinical indicator of an underlying systemic hypercoagulable state. The Factor V Leiden PCR test is a critical component of the diagnostic panel used to evaluate these complex cases, helping to establish a definitive etiology and direct targeted therapeutic interventions.

Family History of Thrombophilia or Clotting Disorders

A strong family history of venous thromboembolism, especially among first-degree relatives (parents, siblings, or children) who developed clots at a young age, is a compelling reason to perform the Factor V Leiden PCR test. Additionally, if a family member has already been diagnosed with the Factor V Leiden mutation, genetic screening may be recommended for other relatives. This is particularly important for female relatives who are considering the use of estrogen-containing oral contraceptives or hormone replacement therapy (HRT), as the combination of the genetic mutation and exogenous estrogen exponentially increases the risk of developing a life-threatening blood clot.

What Does a Factor V Leiden (FVL) Mutation Detection by PCR Detect?

The molecular analysis of the F5 gene at Chughtai Lab provides precise genetic information. The test is designed to detect and characterize several key findings and clinical parameters:

• Wild-Type Genotype (G/G): This finding indicates the absence of the G1691A mutation. Both alleles of the F5 gene are normal, meaning the patient has a standard risk of thrombosis.
• Heterozygous Mutation (G/A): This indicates that the patient has inherited one mutated copy of the F5 gene and one normal copy. This is the most common form of the mutation.
• Homozygous Mutation (A/A): This rare finding indicates that the patient has inherited two copies of the mutated F5 gene (one from each parent), resulting in a severe hypercoagulable state.
• Activated Protein C (APC) Resistance: The PCR test indirectly confirms the genetic basis for hereditary APC resistance, where the factor V protein cannot be cleaved normally.
• Elevated Risk of Deep Vein Thrombosis (DVT): Detection of the mutation correlates directly with an increased propensity for clot formation in the deep veins of the legs.
• Elevated Risk of Pulmonary Embolism (PE): The test identifies individuals at risk for clots breaking free from the legs and traveling to the lungs, causing a life-threatening blockage.
• Genetic Predisposition to Thrombophilia: It establishes a definitive genetic diagnosis of hereditary thrombophilia, distinguishing it from acquired clotting disorders.
• Relative Risk Stratification for Heterozygotes: It identifies individuals who have a 3- to 8-fold increased lifetime risk of developing venous thromboembolism compared to the general population.
• Relative Risk Stratification for Homozygotes: It identifies individuals who have a 50- to 80-fold increased lifetime risk of VTE, requiring aggressive clinical management.
• Co-inherited Genetic Risks: When performed as part of a panel, it helps detect if the patient also carries other mutations, such as the Prothrombin G20210A mutation, which further compounds clotting risk.
• Impact of Estrogen Therapy: It identifies women for whom estrogen-containing birth control pills or hormone replacement therapy would pose an unacceptably high risk of thrombosis.
• Pregnancy-Related Clotting Risk: It detects genetic factors that contribute to placental thrombosis, helping to manage risks of miscarriage and preeclampsia.
• Postoperative Thrombotic Risk: It identifies patients who require mandatory pharmacological thromboprophylaxis during and after major surgical procedures.
• Immobilization-Related Risk: It highlights the need for preventive measures (such as compression stockings or movement) during long-haul travel or bed rest.
• Etiology of Unexplained Neonatal Clots: In rare pediatric cases, it helps diagnose the cause of unexplained thrombosis or purpura fulminans in newborns.
• Need for Long-Term Anticoagulation: The genetic status helps hematologists decide whether a patient who has had a clot needs lifelong blood thinners or a limited course of treatment.
• Carrier Status for Family Planning: It provides valuable genetic information for couples with a family history of thrombophilia who are planning to have children.
• Exclusion of Factor V Leiden: A negative result successfully rules out this specific mutation as the cause of a patient’s clotting event, directing clinicians to look for other causes.
• Interaction with Acquired Risk Factors: It helps clinicians counsel patients on how the genetic mutation interacts with modifiable risk factors like smoking, obesity, and hypertension.
• Guidance for Surgical Prophylaxis: It provides surgeons with critical genetic data to customize post-operative recovery plans and anticoagulant dosing.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid, accurate, and easily accessible diagnostic results. The Factor V Leiden Mutation Detection by PCR is a specialized molecular test that requires sophisticated laboratory processing. Typically, the turnaround time for this genetic analysis is within a few working days, as the process involves DNA extraction, PCR amplification, and expert review by our consultant pathologists. Once the analysis is complete, the report is verified and immediately uploaded to our secure digital database. Patients and their referring physicians receive an automated SMS notification with a direct link to download the report. Reports can also be accessed anytime through the official Chughtai Lab website portal or the Chughtai Healthcare mobile application. For patients who prefer physical copies, reports can be collected from any of our numerous collection centers located across Lahore, Karachi, Islamabad, and other major cities in Pakistan.

Factor V Leiden (FVL) Mutation Detection Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
F5 Gene Allele Status (G1691A)	Wild-Type (G/G) – No mutation detected	Heterozygous (G/A) or Homozygous (A/A) mutation detected
Factor V Protein Cleavage	Normal inactivation by Activated Protein C (APC)	Resistance to cleavage by APC, leading to prolonged active Factor Va
Thrombosis Risk Level	Baseline population risk for venous thromboembolism	3- to 8-fold increased risk (Heterozygous); 50- to 80-fold increased risk (Homozygous)
Pregnancy Complication Risk	Normal obstetric risk profile	Increased risk of recurrent miscarriage, preeclampsia, or placental abruption
Estrogen Therapy Compatibility	Standard risk associated with oral contraceptives/HRT	Contraindicated or highly restricted due to exponentially increased clotting risk
Surgical Prophylaxis Requirement	Standard post-operative care protocol	Mandatory tailored pharmacological thromboprophylaxis recommended
Family Screening Relevance	No immediate genetic screening indicated for relatives	Screening recommended for first-degree relatives, especially females of childbearing age

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Factor V Leiden (FVL) Mutation Detection?

• Experienced Healthcare Professionals: Our molecular biology department is led by highly qualified consultant pathologists and genetic specialists who ensure the highest standards of diagnostic accuracy.
• State-of-the-Art PCR Technology: We utilize advanced real-time Polymerase Chain Reaction instruments to deliver precise and reproducible genetic analyses.
• Patient-Focused Care: From sample collection to report delivery, our team is dedicated to providing a compassionate, comfortable, and seamless experience for every patient.
• Convenient Home Sample Collection: Chughtai Lab offers professional home sample collection services across Pakistan, allowing you to have your blood drawn in the comfort of your home.
• Extensive Diagnostic Network: With hundreds of collection centers nationwide, including major hubs in Lahore, Karachi, and Islamabad, our services are easily accessible.
• Rapid and Secure Online Reporting: Access your genetic test results instantly via our secure online portal, mobile app, or WhatsApp, ensuring timely clinical decisions.
• Strict Quality Control: We adhere to international quality management standards and participate in rigorous external quality assurance programs to guarantee reliable results.
• Comprehensive Diagnostic Approach: Chughtai Lab offers a full suite of hematology and thrombophilia testing, allowing for a complete diagnostic workup under one roof.